Core Insights - The pharmaceutical retail industry is entering a critical reshuffling period, with companies like Kew Flower Pharmaceutical (葵花药业) demonstrating strategies for survival through the empowerment of terminal sales via super traffic products, particularly in the children's health ecosystem [1][2] Group 1: Market Dynamics - The pediatric traditional Chinese medicine market is experiencing a continuous increase in market share, but there is a significant supply gap on the supply side [1] - The top product, Jin Yin Hua Lu, has achieved a category concentration of 89.2%, becoming a traffic entry point in the heat-clearing and detoxifying market [1] - Xiao Kew Flower Lu has maintained its position as the retail market champion for seven consecutive years, achieving sales growth rates of 35.4% and 38.8% in O2O channels for 2023-2024, significantly surpassing industry averages [1] Group 2: Strategic Collaborations - Kew Flower Pharmaceutical is accelerating its strategic layout in the Guangdong market through deep cooperation with 18 chain enterprises, including Guangzhou Minxin Pharmaceutical and Guangdong Foxin Pharmaceutical, achieving both short-term sales conversion and long-term growth momentum [1] - The high traffic attribute of Xiao Kew Flower Lu, along with full-channel support, provides pharmacies with a powerful tool to enhance customer flow [1] - The collaboration model addresses current growth challenges while also offering possibilities for category expansion [1] Group 3: Future Outlook - The pediatric market's unevenness highlights the value of leading brands, with Xiao Kew Flower Lu meeting the demand for regular heat-clearing and detoxifying scenarios, showcasing strong profitability in its segment [2] - Kew Flower Pharmaceutical aims to focus on channel penetration, product innovation, and digital operations by 2025, leveraging its R&D resources and supply chain capabilities to solidify market leadership [2] - The "brand empowerment + traffic-driven" model not only provides a paradigm for small and medium-sized chain pharmacies to break through but also injects new momentum for sustainable development in the entire industry [2]

Group 1: Financial Performance - In 2024, the company achieved operating revenue of 3.377 billion yuan, a year-on-year decrease of 40.76% [2] - The net profit attributable to shareholders of the parent company was 492 million yuan, down 56.03% compared to the previous year [2] - The proposed cash dividend for 2024 is 5 yuan (including tax) per 10 shares, totaling 59.34% of the net profit attributable to shareholders [2] Group 2: Strategic Adjustments - The company is focusing on channel optimization and has established a self-operated B2B platform "Yao Zhida" to enhance efficiency [3] - The strategic direction remains centered on "one elderly, one child, one woman," with an emphasis on chronic diseases and health products [3] - The company plans to expand its product lines in cardiovascular and rheumatic pain areas while maintaining its strengths in digestive system products [3] Group 3: Market Adaptation - The company is adapting to demographic changes, particularly the aging population, by enhancing its product positioning in the elderly care sector [3] - New sales strategies for products like ibuprofen suspension and polyethylene glycol 3350 are being developed to leverage market opportunities [3] - The company is exploring new sales channels, including self-operated e-commerce and direct supply to terminals, to create a multi-dimensional channel system [3] Group 4: Investor Relations - The company emphasizes continuous returns to investors, having distributed dividends exceeding the IPO financing amount since its listing [3] - The management remains committed to maintaining a sustainable return strategy while considering the company's operational status [3] - The company aims to improve operational efficiency and quality through effective implementation of its strategies, ensuring long-term healthy development [3]

Corporate Governance - The company held two shareholder meetings in 2024, reviewing 16 agenda items, all of which were approved [2] - The company continuously improved its governance system, optimizing 26 governance rules to ensure scientific decision-making and operational compliance [2] Information Disclosure and Investor Protection - The company strictly adhered to relevant regulations for information disclosure, ensuring timely and accurate reporting of significant operational information [3] - Various communication channels were established with investors, including a hotline, dedicated email, and investor interaction platforms [3] Strategic Planning for 2025 - The company aims to implement its "One Elderly, One Child, One Woman" strategy, focusing on traditional Chinese medicine, chemical and biological preparations, and health products [4][5] - The strategy emphasizes enhancing product offerings in the elderly care, chronic disease, and women's health sectors [4][5] Organizational Structure and Marketing Strategy - The company plans to optimize its marketing organization, aligning market and sales systems to enhance user engagement [7] - A user-centered approach will be adopted, focusing on efficient service delivery and brand recognition [7] Production and Quality Assurance - The company will implement the "Ten Steps to Quality Medicine" to ensure product quality and efficacy [8] - Emphasis will be placed on lean and flexible production methods to enhance efficiency while maintaining high standards [8] Research and Development Strategy - The company will continue its "Buy, Improve, Collaborate, Research, and Substitute" strategy to enhance its R&D pipeline [9] - Focus will be on advancing in-progress products and exploring external expansion opportunities in core areas [9] Digital Transformation - The company is committed to advancing its digital transformation, creating a user-centered digital marketing ecosystem [10] - Integration of information technology and AI will be prioritized to enhance operational efficiency and management quality [10] Financial Overview - As of December 31, 2024, the company reported total assets of 582,587.60 million, with liabilities of 123,587.68 million and equity of 458,999.92 million [13] - The total revenue for 2024 was 337,704.77 million, with a net profit of 50,273.15 million [13]

Core Viewpoint - In 2024, the company focused on maintaining shareholder interests and adhering to regulatory standards, emphasizing sustainable development and operational efficiency in the pharmaceutical industry [1][2]. Group 1: 2024 Annual Performance - The company reported total assets of 582,587.60 million yuan and net assets attributable to shareholders of 437,913.87 million yuan by the end of 2024 [2]. - The company achieved operating revenue of 337,704.77 million yuan and a net profit attributable to shareholders of 49,204.54 million yuan in 2024 [2][3]. Group 2: Operational Measures - The management team optimized organizational strategies to drive long-term stable growth, focusing on structural adjustments and dynamic strategy changes [3]. - The company implemented a marketing model centered on "brand pull, prescription lead, OTC push, and guerrilla tactics," emphasizing product quality and academic support [3][4]. Group 3: Brand and Marketing Strategy - The company adopted a dual-brand strategy with "Kuwaihua" and "Xiaokuwaihua," enhancing brand recognition through quality products and innovative marketing [6][7]. - The marketing strategy focused on specific demographics, particularly the elderly, children, and women, to drive product sales and brand loyalty [6][25]. Group 4: Digital Transformation - The company is actively embracing digital transformation, establishing a digital supply chain platform and enhancing operational efficiency through data sharing [8][9]. - A strategic vision for digital operations was outlined, aiming to integrate various business functions into a cohesive digital platform [8]. Group 5: Research and Development - The company emphasized a multi-faceted R&D approach, focusing on acquiring and developing competitive products in pediatric, adult digestive, and gynecological treatments [10][12]. - Ongoing projects include nearly forty chemical drug varieties and several traditional Chinese medicine projects, with some already in production and registration stages [12]. Group 6: Compliance and Governance - The company strengthened its compliance framework, enhancing its audit and oversight systems to ensure regulatory adherence and protect shareholder interests [16][17]. - The board of directors was restructured, ensuring a diverse skill set and compliance with legal requirements [20][21]. Group 7: Profit Distribution - The company proposed a cash dividend of 5 yuan per 10 shares, totaling 292 million yuan, which represents 59.34% of the net profit attributable to shareholders for 2024 [52][53].

葵花药业集团股份有限公司 2024 年度独立董事述职报告 本人赵燕，作为葵花药业集团股份有限公司（以下简称"公司"或"本公司"） 的独立董事，任职以来，本人严格按照《公司法》、《上市公司独立董事管理办 法》、《深圳证券交易所股票上市规则》等相关法律法规和规章制度的规定，勤 勉尽责地履行独立董事职责，为公司经营发展提供专业建议，维护公司和全体股 东特别是中小股东的合法权益。现将 2024 年度本人履职情况报告如下： 一、 关于独立性自查情况 经公司 2024 年第一次临时股东大会选举，本人于 2024 年 6 月 25 日起担任 公司第五届董事会独立董事。 经对自身独立性情况进行自查，本人未在公司担任除独立董事及董事会专门 委员会外的其他职务，与公司及其主要股东、实际控制人不存在直接或间接利害 关系，或者其他可能影响独立客观判断的情形，符合《上市公司独立董事管理办 法》等规定的独立性要求。 二、 出席会议情况 本人出席会议情况如下： 1、董事会、股东大会 | 赵燕 | | | 出席董事会情况 | | | 列席股东大会 情况 | | --- | --- | --- | --- | --- | --- | --- ...

葵花药业集团股份有限公司 2024 年度独立董事述职报告 本人作为葵花药业集团股份有限公司（以下简称"公司"或"本公司"）的 独立董事，2024 年任职期间严格按照《公司法》、《上市公司独立董事管理办 法》、《公司章程》等相关法律法规和规章制度的规定和要求，密切关注和维护 全体股东特别是中小股东的利益，恪尽职守、勤勉尽责的履行工作，按时出席任 职期间的各项有关会议，对公司经营管理及业务发展提出积极的意见和建议，充 分发挥独立董事的专业作用。 现将 2024 年度本人履职情况报告如下： 一、 关于独立性自查情况 本人作为公司第四届董事会独立董事，于 2024 年 6 月 25 日因换届离任公司 独立董事职务。在 2024 年度任职期间内，本人不存在影响自身独立性的情形， 任职符合《上市公司独立董事管理办法》等规定的独立性要求。 二、 出席会议情况 本人出席会议情况如下： 1、董事会、股东大会 | 崔丽晶 | 应参加董事 | 出席董事会情况 亲自出席 委托出席 | 缺席次数 | 是否连续两次 | 列席股东 大会情况 列席股东 | | --- | --- | --- | --- | --- | --- | | | ...

葵花药业集团股份有限公司 2024 年度独立董事述职报告 本人缪嘉军，于 2024 年 6 月 25 日经葵花药业集团股份有限公司（以下简称 "公司"或"本公司"）2024 年第一次临时股东大会选举成为公司第五届董事 会独立董事。在任职公司独立董事以来，本人严格按照《公司法》、《上市公司 独立董事管理办法》、《深圳证券交易所股票上市规则》等相关法律法规及《公 司章程》等制度的规定和要求，恪尽职守、勤勉尽责的履行独立董事的职责和义 务，切实有效维护公司全体股东特别是中小股东的合法权益。 现将 2024 年度本人履职情况报告如下： 一、关于独立性自查情况 本人作为公司独立董事，对自身独立性情况进行自查。2024 年度，本人未 在公司担任除独立董事及董事会专门委员会外的其他职务，与公司及其主要股东、 实际控制人不存在直接或间接利害关系，或者其他可能影响独立客观判断的情形， 符合《上市公司独立董事管理办法》等规定的独立性要求。 二、出席会议情况 本人出席会议情况如下： 1、董事会、股东大会 | | | | 出席董事会情况 | | | 列席股东大会 | | --- | --- | --- | --- | --- | - ...

葵花药业集团股份有限公司 2024 年度独立董事述职报告 本人张盈，作为葵花药业集团股份有限公司（以下简称"公司"或"本公司"） 的独立董事，本人始终恪守资本市场监管要求，以投资者权益保护为核心，本着 对全体股东负责的原则，勤勉尽责的履行独立董事的职责和义务，充分发挥独立 董事的独立作用，维护公司及全体股东尤其是中小股东的合法权益。 现将 2024 年度本人履职情况报告如下： 一、 关于独立性自查情况 本人于 2024 年 6 月 25 日经公司 2024 年第一次临时股东大会选举成为公司 第五届董事会独立董事。本人对自身独立性情况进行自查，本人未在公司担任除 独立董事及董事会专门委员会外的其他职务，与公司及其主要股东、实际控制人 不存在直接或间接利害关系，或者其他可能影响独立客观判断的情形，符合《上 市公司独立董事管理办法》等规定的独立性要求，不存在影响独立性的情况。 二、 出席会议情况 本人出席会议情况如下： | | | | 出席董事会情况 | | | 列席股东大会 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 情况 | | 张盈 ...

2024 年度独立董事述职报告 本人作为葵花药业集团股份有限公司（以下简称"公司"或"本公司"）的 独立董事，本年度任职期间严格按照《公司法》、《上市公司独立董事管理办法》、 《公司章程》等相关法律法规和规章制度的规定和要求，忠实履行职责，审慎发 表表决意见，从专业角度为公司经营发展提出建议，充分发挥独立董事作用，切 实保障公司及股东特别是中小股东的合法权益。 现将 2024 年度本人履职情况报告如下： 一、 关于独立性自查情况 本人作为公司第四届董事会独立董事，于 2024 年 6 月 25 日因换届离任公 司独立董事职务。在本人年度任职期内，本人及本人直系亲属、主要社会关系 均未在公司或公司附属企业任职，不直接或间接持有公司股份，未与上市公司 及其控股股东、实际控制人或者其各自的附属企业有重大业务往来，不存在为 公司及其控股股东、实际控制人或者其各自附属企业提供财务、法律、咨询、 保荐等服务的情形。 本人任职符合《上市公司独立董事管理办法》规定的独立性要求，在履职 中始终保持客观、独立的专业判断。 葵花药业集团股份有限公司 2、董事会专门委员会 | | 战略委员会 | | 薪酬与考核委员会 | | | - ...

葵花药业集团股份有限公司 2024 年度独立董事述职报告 本人施先旺，作为葵花药业集团股份有限公司（以下简称"公司"或"本公 司"）第四届董事会独立董事，于 2024 年 6 月 25 日因公司换届离任公司独立董 事职务。2024 年度本人任职独立董事期间，始终坚持独立性原则，确保公平合 理履职，按时参加各项相关会议，审慎审议会议议案，严格按照《公司法》、《上 市公司独立董事管理办法》、《公司章程》等相关法律法规和规章制度的规定和 要求，充分发挥独立董事作用，忠诚维护公司整体利益和全体股东特别是中小股 东的合法权益。 现将 2024 年度本人履职情况报告如下： 一、 关于独立性自查情况 年度任职期间内，本人及本人直系亲属、主要社会关系均未在公司或公司附 属企业任职，不直接或间接持有公司股份，未与上市公司及其控股股东、实际控 制人或者其各自的附属企业有重大业务往来，不存在为公司及其控股股东、实际 控制人或者其各自附属企业提供财务、法律、咨询、保荐服务等不符合《上市公 司独立董事管理办法》规定的独立性要求的情形。 同时，作为第四届董事会审计委员会召集人、提名委员会委员，本人出席了 审计委员会、提名委员会的各次会议 ...